Bayer To Settle Monsanto Litigation, Retains Capacity For Deals

The health care and crop science conglomerate will pay up to $10.9bn to resolve most Roundup claims, but still has capital to do bolt-on deals like last year’s BlueRock cell therapy buy.

A court gavel on 100 bills - legal concept
Bayer will pay $10bn-plus to settle Monsanto's Roundup litigation • Source: Shutterstock

Bayer AG finally removed a major overhang on 24 June with the announcement that it has come to agreements to settle litigation it took on through the acquisition of agriculture company Monsanto Co. for $66bn in 2018. The uncertainty over how much Bayer eventually would pay out to resolve these lawsuits has impacted the company’s value as investors worried it would not have the capacity to invest in growth, particularly in its pharmaceuticals business, but executives insist this is now not the case.

Bayer will pay $10.1bn-$10.9bn to resolve the majority of lawsuits claiming that weed-killer Roundup causes non-Hodgkin lymphoma and up to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Legal & IP

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.